Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Center for Health Advancement, Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, USA.
J Gen Intern Med. 2024 May;39(7):1149-1155. doi: 10.1007/s11606-023-08502-y. Epub 2023 Nov 14.
Sub-optimal HbA1c control is a driver of disparities in diabetes outcomes among Hispanic patients. Differences in medication adherence may underlie racial/ethnic differences in HbA1c level.
To examine the relationship between medication adherence and disparities in HbA1c level among Hispanic patients, relative to other racial/ethnic groups, obtaining care in the University of California Health System (UC Health).
This study used clinical, administrative, and prescription dispensing data (January-December 2021) derived from the electronic health records of 5 Academic Medical Centers in UC Health, and linear regression models (LRMs) to conduct a cross-sectional analysis of the association between medication adherence, race/ethnicity, and HbA1c level. Adjusted LRMs were run with and without the measure of medication adherence to assess this relationship.
Patients with a UC Health primary care physician (PCP), with ≥ 1 PCP visit within the last 3 years, ages 18-75, reporting Asian, Hispanic, or White race/ethnicity, and who had ≥ 2 encounters with an ICD diagnosis of diabetes or had a prescription for a diabetes medication within the last 2 years, as of 12/31/21 (N = 27, 542; Asian = 6253, Hispanic = 7216, White = 14,073).
Our measure of medication adherence was the proportion of days covered (PDC) for diabetes medications in 2021. Our outcome was the most recent HbA1c value.
In the LRM excluding the PDC, Hispanic ethnicity was positively associated with HbA1c level (β = 0.31, p = < 0.001). In the LRM model including PDC, PDC was negatively associated with HbA1c level (β = - 0.18, p = < 0.001). However, the positive relationship between Hispanic ethnicity and HbA1c level did not change (β = 0.31, p = < 0.001).
The findings of this study suggest that the relationship between Hispanic ethnicity, HbA1c level, and factors outside of medication adherence should be explored among primary care patients receiving care in Academic Medical Centers.
HbA1c 控制不理想是西班牙裔患者糖尿病结局存在差异的一个驱动因素。药物依从性的差异可能是 HbA1c 水平存在种族/民族差异的原因。
本研究旨在检验在加利福尼亚大学健康系统(UC Health)接受治疗的西班牙裔患者与其他种族/民族群体相比,药物依从性与 HbA1c 水平差异之间的关系。
本研究使用了临床、行政和处方配药数据(2021 年 1 月至 12 月),这些数据来源于 UC Health 五所学术医疗中心的电子健康记录,并使用线性回归模型(LRMs)对药物依从性、种族/民族和 HbA1c 水平之间的关联进行横断面分析。调整后的 LRMs 分别在包含和不包含药物依从性测量的情况下进行运行,以评估这种关系。
研究对象为有 UC Health 初级保健医生(PCP)的患者,在过去 3 年内至少有 1 次 PCP 就诊,年龄在 18-75 岁之间,报告亚洲、西班牙裔或白人种族/民族,并且在过去 2 年内至少有 2 次 ICD 糖尿病诊断或有糖尿病药物处方,截至 2021 年 12 月 31 日(N=27542;亚洲=6253,西班牙裔=7216,白人=14073)。
我们的药物依从性测量是 2021 年糖尿病药物的天数覆盖率(PDC)。我们的结果是最近的 HbA1c 值。
在不包含 PDC 的 LRM 中,西班牙裔种族与 HbA1c 水平呈正相关(β=0.31,p<0.001)。在包含 PDC 的 LRM 模型中,PDC 与 HbA1c 水平呈负相关(β=−0.18,p<0.001)。然而,西班牙裔种族与 HbA1c 水平之间的正相关关系并未改变(β=0.31,p<0.001)。
本研究结果表明,在接受学术医疗中心初级保健治疗的患者中,应进一步探讨西班牙裔种族、HbA1c 水平和药物依从性以外因素之间的关系。